Enleofen
Singapore, Singapore· Est.
Enleofen develops IL‑11‑targeted therapeutics to treat fibro‑inflammatory diseases using a patient‑driven discovery platform.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Enleofen develops IL‑11‑targeted therapeutics to treat fibro‑inflammatory diseases using a patient‑driven discovery platform.
FibrosisInflammatory diseasesOrgan dysfunction
Technology Platform
Patient‑centric discovery platform that integrates human genetic data, disease‑relevant biology, and extensive safety profiling to develop IL‑11 pathway antagonists.
Opportunities
IL‑11 targeting could address large unmet needs in chronic fibrotic diseases, offering potential disease‑modifying therapies across multiple organ systems.
Risk Factors
Early‑stage preclinical status, high capital requirements, and competition from established anti‑fibrotic programs pose significant execution risks.
Competitive Landscape
Few companies focus specifically on IL‑11, giving Enleofen a differentiation edge, though larger biotech and pharma firms are advancing alternative fibrosis pathways.